Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

A high-level overview of Blueprint Medicines Corporation (BPMC) stock. View (BPMC) real-time stock price, chart, news, analysis, analyst reviews and more.

(STAT News) How a dinner in Paris revived talks for Sanofi’s $9.5 billion deal for Blueprint Medicines. For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

In a report released today, David Lebowitz from Citi reiterated a Buy rating on Incyte (INCY – Research Report), with a price target of $88.00. The company’s shares opened tod ...

Stay up to date on how Blueprint Medicines Corp (BPMC:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

In today's episode of *Blueprint Explosive Exclusive* with anchor Meghna Deka, the discussion revolves around the tragic ...

Financing is the engine of development. And right now, this engine is sputtering,” U.N. Secretary General António Guterres ...